Total Pelvic Exenteration for Gynecologic Malignancies by Diver, Elisabeth J. et al.
 
Total Pelvic Exenteration for Gynecologic Malignancies
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Diver, Elisabeth J., J. Alejandro Rauh-Hain, and Marcela G. del
Carmen. 2012. Total pelvic exenteration for gynecologic
malignancies. International Journal of Surgical Oncology
2012:693535.
Published Version doi:10.1155/2012/693535
Accessed February 19, 2015 10:45:36 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436316
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAHindawi Publishing Corporation
International Journal of Surgical Oncology
Volume 2012, Article ID 693535, 9 pages
doi:10.1155/2012/693535
Review Article
Total Pelvic Exenteration for GynecologicMalignancies
ElisabethJ. Diver,J. AlejandroRauh-Hain,andMarcela G.del Carmen
Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School,
55 Fruit Street, Yawkey 9E Boston, MA 02114, USA
Correspondence should be addressed to Marcela G. del Carmen, mdelcarmen@partners.org
Received 24 February 2012; Accepted 10 April 2012
Academic Editor: Constantine P. Karakousis
Copyright © 2012 Elisabeth J. Diver et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Totalpelvicexenteration(PE)isaradicaloperation,involvingenblocresectionofpelvicorgans,includingreproductivestructures,
bladder, and rectosigmoid. In gynecologic oncology, it is most commonly indicated for the treatment of advanced primary or
locally recurrent cancer. Careful patient selection and counseling are of paramount importance when considering someone for PE.
Part of the evaluation process includes comprehensive assessment to exclude unresectable or metastatic disease. PE can be curative
forcarefully selected patients with gynecologic cancers. Majorcomplications can beseen in as manyas 50% of patients undergoing
PE, underscoring the need to carefully discuss risks and beneﬁts of this procedure with patients considering exenterative surgery.
1.Introduction
Pelvic exenteration (PE) describes a radical surgery involving
the en bloc resection of the pelvic organs, including the
internal reproductive organs, bladder, and rectosigmoid.
Indications include advanced primary or recurrent pelvic
malignancies, most commonly centrally recurrent cervical
carcinoma, but also other gynecologic tumors and urologic
and rectal cancers. Distant metastasis has traditionally been
a contraindication to PE with curative intent. As the best
chance for disease-free survival is surgical resection of re-
gional disease, this procedure is an opportunity to cure
advancedandrecurrentcancersconﬁnedtothepelvis.PEhas
alsobeenusedforpalliationofsymptomsrelatedtoradiation
necrosis or extensive tumor burden. Both total and partial
PE require extensive reconstruction and surgical recovery
with signiﬁcant associated morbidity and mortality. Careful
patient selection is required to balance the potential goal of
cure or symptom palliation with surgical risk.
T h eﬁ r s tc a s e so ft o t a lP Ew e r ed e s c r i b e db yB r u n s c h w i g
in 1948 as a palliative procedure for symptoms caused by
locally advanced gynecologic cancers. This demonstrated
proofofconceptforPE,withapostoperativesurvivalofupto
8 months, and a 23% surgical mortality rate [1]. Subsequent
data demonstrated that the technique could oﬀer a chance of
cure for centrally located tumors, not just palliation, and the
focus of the surgery shifted to one of curative intent. Various
surgical approaches both for sparing uninvolved pelvic
organs and removing extraperitoneal structures such as
the sacrum were attempted. Major breakthroughs included
separate stomata for urine and fecal diversion and the use
of omentum to protect the empty and denuded pelvic space
and reduce abscess formation and intestinal obstruction
[2, 3]. More recently, techniques to resect tumor involving
the pelvic sidewall, previously a contraindication to PE, have
been described oﬀering more patients a chance at curative
surgery [4]. PE may also be combined with intra-operative
radiation therapy for improved disease control at the pelvic
sidewall or possible positive margins [5, 6].
Since 1948 several developments in perioperative care
and surgical technique have improved survival, morbidity,
and mortality, with recent mortality rates quoted <5%.
Development of continent urinary conduits and orthotopic
neobladders, as well as low rectal anastomoses has led to
the completion of PE without formation of stomata [7].
Various techniques for functional neovaginas have been
described, allowing patients to maintain sexual function if
they desire. Advances in laparoscopic and robotic assisted
technology applied to PE have improved operative recovery.
Despite these signiﬁcant advances and ﬁve-year survival
rates of approximately 50%, PE remains a radical procedure
with signiﬁcant complications (31–92%; see Table 1), both2 International Journal of Surgical Oncology
Table 1: Recent series of pelvic exenteration for gynecological malignancies.
Author Year N Cervical Uterine Vulvar Vaginal Ovarian Early
complications
Late
complications
Severe
morbidity
Operative
mortality
5-year
survival
Benn et al. [60] 2011 54 40 9 5 0 0 50% 61% 44% 34%
Maggioni et al. [61] 2009 106 62 10 9 21 4 48% 49% 0%
Marnitz et al. [12] 2006 55 55 0 0 0 0 11% 75% 38% 6% 37%
Goldberg et al. [11] 2006 103 95 2 1 0 0 25% 1% 47%
Sharma et al. [62] 2005 48 39 2 3 2 2 27% 75% 45% 4% 30%
Berek et al. [10] 2005 75 67∗ 80∗ 0 23% 4% 54%
∗Combined cervical and vaginal cancers.
physical and psychological [8]. Given the nature of this
procedure, appropriate patient selection and counseling
remain paramount.
2. Indicationsand Outcomes
2.1. Cervical Cancer. Traditionally PE has been used for
centrally recurrent cervical carcinoma, both squamous and
adenocarcinoma, with well-documented salvage potential.
Up to 25% of women with FIGO stage IB-IIA cervical
cancer may recur after initial therapy [9]. Frequently, these
recurrences may be treated with radiotherapy; however, rad-
ical surgery may oﬀer an alternative for curative treatment.
Survival rates ranging from 16 to 60% are reported for these
patients [10, 11]. Long-term survival is directly correlated
with complete tumor resection [12, 13], so establishing
resectability is a key aspect of preoperative planning. Time
from primary treatment, with radiation or chemoradiation,
to time of PE has also been shown to be related to survival
and disease-free interval [12], with women requiring PE
for recurrence less than 2 years following primary therapy
demonstrating an 8-month survival versus 33 months in
women who recurred more than 2 years following initial
treatment in one study [14], though this has not been shown
in all series [10]. PE has also been utilized as a potentially
curative primary treatment for locally advanced cervical
cancer(FIGOstageIVa),apracticeexercisedmorefrequently
inGermanythantheUnitedStates[15].Forexample,intheir
series, Marnitz et al. reported a 52.5% ﬁve-year survival [12].
2.2. Uterine Cancer. Cases of PE for a variety of histologic
types of uterine cancer have been reported, with outcomes
similar to PE for other indications. Most recurrent uterine
cancers spread beyond the pelvis, given their propensity
for diﬀuse abdominal or heterogenous spread, making PE
appropriate intervention for only a select group of patients
with recurrent uterine malignancies. Women with only loco-
regional recurrence, however, may be candidates for PE with
curative intent. Khoury-Collado et al. [16] described a series
of 21 women with recurrent uterine cancers who underwent
PE and demonstrated a ﬁve-year survival of 40%. The study
also noted varying outcomes dependent on histology, with
endometrioid adenocarcinoma (50% ﬁve-year survival rate)
and sarcoma (66% ﬁve-year survival rate) demonstrating
improved survival over a group of women with tumors
withserous,mixed,andcarcinosarcoma-histology(14%ﬁve-
year survival rate). Morris et al. [17]r e p o r t e daﬁ v e - y e a r
survival rate of 45% following PE for recurrent endometrial
cancer. Given the similarity of complication rates (48–60%)
and survival to PE for cervical cancer, patients with locally
recurrent uterine cancer may be considered candidates for
the procedure.
2.3. Vulvar Cancer. Vulvar cancer has a propensity for
regional metastases. For patients with advanced primary
or recurrent vulvar cancer who do not have the option of
treatment with radiation therapy, PE may be appropriate.
Forner and Lampe [18] published a series of 27 patients
undergoing PE. The authors demonstrated results similar
to other gynecologic malignancies, with a ﬁve-year survival
of 62%. Complete resection with no evidence of residual
disease was associated with improved outcomes, a ﬁve-year
survival rate of 74%, compared to 21% in patients without
complete resection. Absence of tumor lymph node invasion
was also associated with an improved ﬁve-year survival rate
(83% versus 36%). In contrast, combination therapy with
vulvectomy and radiotherapy has been described for locally
advanced vulvar cancer with the goal to spare the pelvic
organs, with ﬁve-year survival in two series of 45% and
72%, and sparing of the pelvic organs in 62.5% and 89% of
patients [19, 20].
2.4. Ovarian Cancer. Given the propensity of ovarian cancer
to spread throughout the abdomen, women with this disease
are rarely candidates for PE with curative intent. Supraleva-
tor PE has been reported when needed for optimal cytor-
eduction, combined with standard staging procedures and
for recurrent disease. Two series of modiﬁed posterior PE
for ovarian cancer demonstrated median survival 33 and
37.4 months after initial surgery. Optimal cytoreduction was
achieved in 46% and 58% of patients in the series [21, 22],
demonstratingthistechniquemaybeusedtoachieveoptimal
cytoreduction in patients with disease requiring rectosig-
moid resection.
2.5. Vaginal Cancer. As vaginal cancer is rare, this review
couldnotidentifyanyliteraturespeciﬁcallyaddressingPEfor
this indication. Several cases of vaginal cancer, both primary
and recurrent, undergoing PE have been included in larger
studies, most frequently including the results for theseInternational Journal of Surgical Oncology 3
patients combined with results for cervical cancer [10, 23]. It
may be hypothesized, that results following PE for vaginal
carcinoma would be similar to those for cervical cancer pro-
vided the same other parameters for patient selection apply.
2.6. Palliative PE. PE has been described for palliation rather
than for curative intent, most frequently in the setting of
severe radiation necrosis. Indications have also included
intractable hemorrhage due to tumor invasion and ﬁstulae.
Both morbidity and mortality were shown to be higher in
this group of patients as opposed to those undergoing PE
with curative intent, though improvements in quality of
life are reported [24, 25]. PE is thus only considered for
palliation if there is no reasonable alternative, though with
the development of minimally invasive surgical technology,
PE may become a more feasible option [26].
3.PatientSelectionandPreoperativeScreening
PE is a major surgery with signiﬁcant morbidity, and as such
selecting appropriate patients is essential. If the surgery is
undertaken with curative intent, the tumor should be fully
resectable with negative margins. Recurrence should be
biopsy-proven. Classically, disease burden was required to
be limited to the central pelvis, but with new surgical de-
velopments candidates for curative PE may now also include
patients with positive lymph nodes, pelvic sidewall involve-
ment, and local bone invasion.
Regardless of the indication, patients undergoing PE
must be in otherwise good medical health to be able to
tolerate a long surgical procedure with extensive ﬂuid shifts
and prolonged hospital stay. Major medical comorbidities
may be a potential contraindication to PE. Preoperative
evaluation includes a complete history, physical exam, and,
if necessary, an exam under anesthesia, biopsy of any
suspiciouslesionsuchasanenlargedlymphnode,evaluation
of speciﬁc patient concerns suggesting metastatic spread,
such as unilateral leg pain, chest radiograph or computed
tomography(CT).Ingeneral,cystoscopyandsigmoidoscopy
are not necessary unless the bladder or rectum is to be
spared. In this case, careful evaluation of these structures is
imperative to rule out occult metastatic disease.
Laboratory tests should include a complete blood count,
platelet count, comprehensive metabolic panel, including
hepatic and renal function, as well as clotting factors and
urinalysis. Elevated liver function tests require further eval-
uation to rule out liver metastasis. Patients with a bleeding
diathesis and any anemia should have their anemia cor-
rected preoperatively. Any infectious process should be fully
evaluated and whenever possible resolved preoperatively.
Patients with underlying diabetes should have their glucose
control optimized before PE. Patients should be oﬀered
testing for human immunodeﬁciency virus, which may be a
contraindication to PE.
Patients being considered for pelvic PE need to be care-
fully counseled. Given the nature of the surgery, patients
should be counseled about changes in body image and
function. Speciﬁcally, patients should have an understanding
of anatomical changes involving creation of colostomy and
urinary conduit and need to be accepting of major changes
in body image even in the setting of reconstructive surgery.
Patients require signiﬁcant family support, intact mental
capacityandaccesstocontinuedandlong-termmedicalcare.
We recommend sharing printed literature and illustrations
depicting ostomies and conduits, as well as oﬀering patients
the opportunity to speak with other women who have
undergone the procedure. Patients should meet with ostomy
nursing staﬀ to begin the education process preoperatively
and gain conﬁdence with management of the ostomy and
conduits. During these visit, patients can be marked for
optimal placement of the ostomy and conduit. Part of the
counseling sessions should focuson sexual functionand how
this will change for both patients choosing to have creation
of a neovagina, as well as for those declining this part of
the reconstruction. A formal psychiatric consultation may be
appropriate for some patients.
Patients should be informed of all possible perioperative
complications, including infectious, thromboembolic, gas-
trointestinal, urinary, psychiatric, readmission, and reoper-
ation. Women being considered for PE should be informed
of a 3–5% risk of operative mortality. Importantly, as noted
by Khoury-Collardo et al. [16] some of these complications
occur more frequently in the remote postoperative period
(days31–90)thanintheimmediateone(0–30days).Patients
should expect frequent visits to the hospital during this time
giventherisknotonlyofimmediatebutalsodelayedcompli-
cations. Of note, part of the preoperative counseling should
include the impact aborting the operation for unexpected
surgical ﬁndings may have on the patient. That is, patients
should be informed that even with the use of state-of-the art,
preoperative imaging, the possibility of ﬁnding metastatic
disease continues to exist, and a minority of exenterative
procedures are aborted at the time of surgical exploration. It
is critical that patients have suﬃcient medical and emotional
support to manage the physical and psychological challenges
central to the operation [27].
3.1. Imaging. The presence of metastasis outside the pelvis
is an absolute contraindication to PE. Therefore, the goal of
diagnostic techniques is to ﬁnd evidence of unresectable or
metastatic disease; thus, making the woman an unsuitable
candidate for PE. A number of diagnostic techniques can aid
in assessing unresectable disease in a patient who is believed
to have central pelvic disease. Computed tomography (CT)
and magnetic resonance imaging (MRI) can be helpful in
assessing the presence of lateral pelvic wall invasion or liver
metastasis. However, major limitations of CT and MRI lie in
their inability to assess minimally enlarged nodes to detect
microscopic peritoneal disease and to distinguish ﬁbrosis
from tumor in recurrent disease, and the fact that most
patients have usually received extensive radiation makes
distinguishing radiation ﬁbrosis from malignant tumor
extremely diﬃcult [28].
F-ﬂuorodeoxyglucose positron emission tomography
(FDGPET)hasbeenshowntoperformbetterinthispopula-
tion. The only prospective study to date in which all patients4 International Journal of Surgical Oncology
underwent surgical exploration with curative intent and in
which almost all PET positive sites were biopsied showed
that sensitivity and speciﬁcity of PET imaging in metastatic
disease in patients being considered for PE was 100 and 73%,
respectively. Despite a negative predictive value of 100%,
positivepredictivevaluewas55%.Thehighfalsepositiverate
found in this study makes surgery obligatory for all PE
candidates [29]. Bone scans are usually not indicated unless
there is a history of recent bone pain and concern for bony
metastases.
3.2. Explorative Phase. The procedure begins with the
patient in low lithotomy position to allow for abdominal
and perineal portions of the surgery. Combined epidural
and general anesthesia may be considered for additional
postoperative pain control. PE is traditionally performed as
an open abdominal procedure, but recent developments in
laparoscopy and robotics have allowed for the minimally-
invasive adaptation of the technique. Open technique will
be described here. The abdomen is opened with a vertical
midline incision to allow for maximum ability to explore
the upper abdomen as well as the pelvis. The abdomen
and pelvis are then thoroughly examined for evidence of
metastatic disease. Washings may be sent for cytology. Any
suspicious lesion is biopsied and sent for frozen section
to exclude the possibility of distant metastatic disease that
would preclude complete resection or alter the surgical plan.
For recurrent cervical cancer, low para-aortic and pelvic
lymph node dissection may be performed again to preclude
metastatic spread beyond the pelvis. Lateral involvement of
disease to the pelvic sidewall should be assessed at this time.
Once the disease has been conﬁrmed to be resectable, the
operation may proceed [8, 30, 31].
The round ligaments are divided, and the paravesical
and pararectal spaces are developed. At this time the pelvic
sidewalls may again be examined. At this point, the extent
of PE must be determined. Total PE includes removal of the
bladder and distal ureters, portions of rectum and sigmoid
colon, internal reproductive organs (if still present), and
vagina. In well-selected patients, this procedure generally
ensures complete negative margins from the tumor speci-
men. Occasionally, if the anatomic location of the recurrence
is only the anterior or posterior compartment of the pelvis,
the colon or bladder may be spared and only an anterior
exenteration or posterior exenteration may be necessary.
3.3. En Bloc Resection. Removal of the specimen begins with
the ligation and division of the ﬁbrovascular pedicle con-
taining the uterine vessels, cardinal ligament, and the ureter
bilaterally. The uterine artery is ligated at is origin from
the hypogastric, lateral to the ureter. The infundibulopelvic
ligaments are ligated above the level of the common iliac
vessels. The sigmoid is then mobilized and transected with a
gastrointestinal anastomotic stapler (GIA), and the sigmoid
vessels are identiﬁed and ligated. Care must be taken to
preserve blood ﬂow to the remaining colon—usually the
sigmoid artery is left intact and the superior hemorrhoidal
artery is ligated. The avascular plane between the sigmoid
and the sacrum is developed to the level of the levator ani
muscles. The prevesical space is extended bluntly. At this
point, the specimen should be freely mobile in the pelvis.
The perineal portion of the procedure is then performed
(or may be performed synchronously with an additional
surgeon). An incision is marked to include the urethra,
vaginal opening, anus, and possibly the vulva. The muscles
of the pelvic ﬂoor are transected circumferentially. The
pubococcygeal and anococcygeal ligaments are identiﬁed
and divided. Upon completion of the dissection, the entire
specimen is free to be removed.
3.4. Alternative Types of PE
3.4.1. Anterior PE. Anterior PE involves the removal of the
bladder and internal reproductive organs but spares the
gastrointestinal tract. The rectosigmoid, anus, and lower
portion of the posterior vagina are left intact. After division
of the cardinal ligaments, uterine vessels, and ureters, the
rectum is separated from the upper vagina. The rectum
is retracted posteriorly by rectovaginal bimanual exam to
ensure the space is clear of tumor and resectable. The
uterosacral ligaments are dissected and divided. An incision
is made into the peritoneum of the cul-de-sac, and the
rectumisdissectedsharplyoﬀtheuppervagina.Theincision
into the posterior vagina at its midportion is made. Biopsies
of the vagina or margins may be sent for frozen section.
3.4.2. Posterior PE. Posterior PE removes the internal repro-
ductive organs and the rectosigmoid but spares the anterior
vagina, urinary bladder, and ureters. In previously irradiated
pelves, it is important to consider the possibility of urinary
ﬁstulae developing following a posterior PE given the pos-
sibility for devascularization. The uterovesical peritoneum
is incised after the paravesical and pararectal spaces have
been developed. The ureters are identiﬁed and dissected
as in a radical hysterectomy, and the uterine arteries and
cardinal ligaments ligated. The anterior vagina is incised and
dissected sharply. The perineal phase of the operation spares
the urethra and the anterior vagina.
Modiﬁed posterior PE, as for cytoreduction in ovarian
cancer, is a supralevator dissection. There is no perineal
phase to the operation. If enough rectum remains (more
than 6 centimeters), a low rectal anastomosis may be made,
sparing the patient a stoma.
3.4.3. Supralevator PE. If the tumor does not involve the
vulva or lower third of the vagina, the patient may be a
candidate for a supralevator PE [10]. After the specimen
is mobilized as in a total PE, an incision is made into the
posteriorvaginalwallbelowthetumor,ensuringanadequate
margin. The rectum is isolated and divided with a stapling
device, leaving an anorectal stump and possibility for low
rectal anastomosis.
3.5. Reconstruction
3.5.1. Urinary Diversion. Brunschwig initially designed re-
construction after PE with an ureterosigmoidostomy, knownInternational Journal of Surgical Oncology 5
as a wet colostomy, with urine and feces emptying through
onestoma[1].Thiswascomplicatedbyinfectionandpatient
dissatisfaction. Subsequently, Bricker developed the isolated
ileal loop conduit [2]. In current practice, both incontinent
ileal and colonic conduits are used, as well as a variety of
continent urinary reservoirs, most commonly the Miami
pouch [30, 31]. The standard ileal conduit is formed by an
isolated segment of distal ileum with its vasculature. The
ureters are anastomosed directly to the ileum at one end, and
the other end is brought to the skin as a stoma. A drainage
bag must be worn over the stoma.
T h eM i a m ip o u c hw a sﬁ r s tr e p o r t e db yB e j a n ya n d
Politano in 1988, a modiﬁcation of prior continent colonic
pouches designed to reduce incontinence [32]. A segment
of distal ileum and ascending colon are used for the pouch.
The ileum is transected 10 to 15 centimeters proximal to the
ileocecal valve, and the transverse colon is transected distal
to the middle colic artery. An appendectomy is performed.
To form the bulk of the pouch, the colon is opened along
the tenia, and the open edges are approximated by folding
the colon segment into a u-shape conduit and the edges
closed with a stapling device. This formation of the colon
creates a reservoir and interrupts the ability of the bowel to
peristalse and increase the pouch pressure. For the ureteral
anastomoses, the distal ends of the ureters are ﬂayed and
then sutured with ﬁne, absorbable suture to the colonic
submucosa. Ureteral stents are placed and secured. Attention
is then turned to the ileum, which is tapered distally to
support the ileocolic valve and prevent reﬂux. The free end
of the ileum is brought to the skin surface as a stoma. The
patient will be required to self-catheterize this stoma, but
she is spared a drainage device if the procedure is successful.
Penalver et al. [33] in a follow-up study of the Miami
pouch reported 92% continence and reservoir volume of
average 650mL, allowing for a reasonable catheterization
interval. Another recent series reported 89% of women were
continent of urine [11].
3.5.2. Fecal Diversion. For patients whose disease requires
infralevatordissectionposteriorly,permanentendcolostomy
will be required because the anal sphincter is compromised
orexcised.Ifthesphincterandenoughrectummaybespared
without compromising the chance at complete disease resec-
tion, low rectal anastomosis may be considered to restore
continence. Direct end to end anastomosis with circular sta-
plers is a reasonable option if enough healthy tissue remains.
To improve frequency of stooling by improving the reservoir
of the rectum, a colonic J-pouch may be used, particularly
in patients with very little rectum remaining (less than 5
centimeters). Some authors, however, cite the frequency of
recurrence of disease near the site of rectal anastomosis
(45%)asareasontoperformcompleteresectionandendcol-
ostomy in all patients [11]. Other authors strongly support
lowrectalanastomosisforachanceatpreservedfunctionand
avoidance of undesirable colostomy for the patient [10].
3.5.3. Neovagina. After vaginectomy, construction of a neo-
vagina for restoration of sexual function should be oﬀered to
patients undergoingPE. Severaloptions exist forthecreation
of a neovagina, including split-thickness skin grafts, myocu-
taneous grafts, and colon. Rectus abdominus myocutaneous
(RAM) ﬂaps have been reported routinely in the literature,
with 93% viability in the series from UCLA [10]. The ﬂap
also serves to ﬁll and vascularize the pelvic dead space.
The RAM ﬂap may be harvested from the same mid-
line vertical incision used for the PE, improving cosmetic
outcomes for the patient. Consideration must be made in
the selection of the ﬂap, such as previous Maylard incision
or other compromise to the inferior epigastric artery. A
transverse or vertical ﬂap may be constructed, at least 10 to
12 centimeters in length, maintaining the blood supply from
the inferior epigastric artery. The ﬂap is freed, elevated, and
sutured into a tube with the skin at the interior, which will
serve as the neovagina. The tube is then secured in the pelvis
at the vaginal introitus. A mold with estrogen cream is left in
the vagina to maintain the lumen for 5 to 7 days. The donor
site is closed with the primary abdominal incision. Results
are positive, with high ﬂap viability [31]. Patient satisfaction
and coitus rates are quoted as 58–78% [34, 35].
3.5.4. Pelvic Floor Coverage. If a neovagina has been created
with a myocutaneous ﬂap, such as a RAM ﬂap, this graft is
usually suﬃcient to ﬁll the pelvic dead space and ensure ade-
quate vascularity. If no such procedure has been performed,
it minimizes complications such as bowel obstruction and
maximizes hemostasis to close the pelvic dead space. The
most common mechanism for coverage is with the omental
J-ﬂap. The omentum is detached at the greater curvature
of the stomach while preserving its origin containing the
left gastroepiploic artery, which will supply the ﬂap. The
omentum is then brought into the pelvic dead space and
sutured into place. Other options, such as mesh and pelvic
packing, were attempted with poor outcomes [11].
4.Laparoscopic andRobotic-Assisted Surgery
Laparoscopic surgery has advanced considerably in recent
years. The indications for its use have widened, and the
superseding of open surgery seems inevitable in many areas
of surgery. This revolution in surgery is in part associated
with the technological advancement and a concomitant
acquisition of advanced minimally invasive surgical skills by
many gynecologic oncologists. Laparoscopy is now a well-
accepted tool in the armamentarium of the treatment of
gynecological cancer, and data have been published by var-
ious centers [36–39]. Minimal invasive surgery is generally
associated with less intraoperative blood loss, postoperative
pain, and shorter hospital stay.
P o m e le ta l .[ 40, 41] were the ﬁrst group to report
two cases of laparoscopic PE for gynecological cancer. The
authors demonstrated in these reports the feasibility of
this procedure. Both patients enjoyed the other well-known
advantages of laparoscopy including minimal blood loss and
quick ambulation, all contributing to a better postoperative
quality of life. Subsequently, Lin et al. [42]r e p o r t e dac a s e
of laparoscopy-assisted transvaginal total PE. In addition,6 International Journal of Surgical Oncology
Ferron et al. [43] published a series of ﬁve patients that
underwent a laparoscopic assisted vaginal PE. Their series
reports the ﬁrst application of a rational combination of
laparoscopic, perineal, and hand-assisted surgery, with the
goal of limiting the potentially long laparoscopic time to a
strict minimum. Of note, the authors elected to perform
a hand-assisted Miami pouch through a minilaparotomy
(5cm) in order to reduce the operative time, safely perform
the ureteral anastomosis, restore bowel continuity and, in
addition, build the omental cylinder for vaginal reconstruc-
tion. The use of a perineal or vaginal approach allowed to
quickly and safely free the specimen well above the pelvic
ﬂoor. In a subsequent report by the same authors, with a
mean follow-up of 14 months, four patients died of the
disease (three were metastatic), one patient presented a local
recurrence, and two patients are disease free [44].
Puntambekar et al. [45]r e p o rt e di nas e r i e so f1 6c o n s e c -
utive patients, the technique, feasibility, and safety of laparo-
scopic anterior PE as primary treatment for locally advanced
pelvic cancers. Thirteen patients underwent anterior PE with
ureterosigmoidostomy, while two patients required total PE
withwetcolostomy.Theauthorsdescribedalowrateofmor-
bidity in their series. Two patients suﬀered from subacute
intestinal obstruction and were treated conservatively. One
patient had a ureteric leak that resolved with conservative
management. Of note, after a mean follow up of 15 months,
all patients were disease free. Puntambekar et al. [46] also
described the feasibility of doing a laparoscopic total PE
for palliation in advanced cervical cancer. Of the 7 patients
included in their series, no patients required conversion to
open surgery. The mean postoperative hospital stay was 8
(7–21) days. The mean followup was 11 (4–24) months and
mean symptom free period was 8 (3–24) months. There was
no major and unanticipated postoperative morbidity. There
was no immediate postoperative mortality. In all patients,
the pathology specimen had tumor free margins. The mean
followup of the patients was 11 months (range 4 to 24
months); and the mean symptom free survival period was 8
months (range 3 to 24 months). Four patients subsequently
died secondary to distant metastases. Three patients are now
disease-free for more than a year.
The development of robotic technology has facilitated
the application of minimally invasive techniques for the
treatment and evaluation of patients with gynecological
cancers. Robotic surgery oﬀers several advantages over lap-
aroscopy: a three-dimensional vision system, wristed instru-
mentation, and ergonomic positioning for the surgeon while
performing surgical procedures. The enhanced visualization
gives the gynecologic surgeon an improved ability to identify
tissue planes, blood vessels, and nerves while performing the
surgical procedure [47–49].
Since the ﬁrst report of robotic-assisted radical hysterec-
tomy by Sert and Abeler in 2006 for cervical cancer, there
have been some reports of robotic-assisted laparoscopic PE
[50–52]. The ﬁrst cases of robotic-assisted laparoscopic PE
weredescribedbyPruthietal.[53]in12womenforclinically
localized bladder cancer. Urinary diversion was performed
extracorporeally (9 ileal conduit diversion, 3 orthotopic neo-
bladder). Lim [54] reported the ﬁrst case report of robotic
assisted total PE with an ileal loop urinary diversion and
an end colostomy for treatment of recurrent cervical cancer.
Subsequently, Lambaudie et al. reported a case series of
three patients that underwent robotic assisted total PE.
Of note, the urinary diversion was made extracorporeally
by a transrectal laparotomy. The authors reported that
concerning hospital stay, there was no beneﬁt comparing
to laparotomy, essentially due to urinary diversion manage-
ment (catheterization) and to self catheterization patient’s
autonomy.
Despitetheapparentencouragingearlyresultssuggesting
an advantage of minimally invasive surgery for PE, questions
remain about the surgical eﬀectiveness of this approach.
Further study of minimally invasive techniques to perform a
PE is needed prior to widespread clinical application of these
techniques.
5. Complications
As it is a radical surgery performed in the setting of advanced
tumor growth and frequently on irradiated tissue, PE is
associated with a signiﬁcant rate of complications, quoted
about 40–50% for major complications and about 80%
for minor complications. Mortality is quoted from 1–16%,
with disparate causes including sepsis, thromboembolic
disease, and cardiopulmonary failure. Despite signiﬁcant
advances in the last ﬁfty years, the extensive nature of the
surgery, including blood loss, ﬂuid shifts, and operative
time, have led to unavoidable risks. Infection is the most
frequent morbidity (19–86%), with urinary infections and
wound infections most commonly reported. Anastomotic
leaks and ﬁstulae from either diverting system are also
relatively frequent, cited at 8–36%. Small bowel and ureteral
obstructions also occur in about 5–10% of patients. Most
of these complications can be managed conservatively, but
signiﬁcant numbers of patients require operative revision
[10, 11, 55]. Death in the perioperative period occurs in
fewer than 5 percent of patients, with women over the age
of 65 at highest risk [10].
6. Postoperative Period
Given the radical and prolonged nature of this proce-
dure, patients and providers must be prepared for a long
and potentially complicated hospital course. Many patients
require a stay in the intensive care unit immediately post-
operatively for close monitoring, particularly in the setting
of potentially dramatic ﬂuid shifts. Blood loss may be
high with transfusion required in most patients [14]. Spe-
cial attention to thromboembolism prophylaxis, respiratory
care, and nutrition is required. While no longer routine,
some patients will require total parenteral nutrition due
to prolonged inability to eat postoperatively, as ileus is
relatively common [56]. A team-based approach, including
case managers, dedicated nurses, and social workers, may
help patients as they heal both mentally and physically
postoperatively.International Journal of Surgical Oncology 7
7. Qualityof Life
As a portion of preoperative counseling and postoperative
support, the changes in a woman’s body image following
PE must be reviewed. Some patients, particularly those
undergoing this surgery for palliative management of pain
or ﬁstulae, do report improved quality of life following
surgery, with decreased narcotic requirements and malodor-
ous discharge [25]. Most women, however, note a decline
in speciﬁc areas of quality of life. Most commonly sexual
quality of life is diminished from preoperatively. Notably,
body image, physical ability, and social function have all be
reported decreased in questionnaires compared to patients’
preoperative answers. These changes are more pronounced
inyoungerpatientsandthosewhodonotundergoingvaginal
reconstruction. Interestingly, overall function and mental
and emotional quality of life are comparable [57–59].
8. Conclusions
PEisaradicaloperation,involvingenblocresectionofpelvic
organs, including reproductive structures, bladder, and rec-
tosigmoid. In gynecologic oncology, it is most commonly
indicated for the treatment of advanced primary or locally
recurrent cancer. Patients need to be carefully selected and
counseled about risks and long-term issues related to the
surgery. A comprehensive evaluation is required in order
to exclude unresectable or metastatic disease. Total PE is
associated with signiﬁcant surgical morbidity, a fact that
underscores the importance of careful patient selection and
counseling. The emergence of minimally invasive surgery
and application of this technology to radical pelvic surgery
including PE may result in a reduction operative morbidity
and mortality. Further studies are necessary prior to a
widespread adoption of this technology to exenterative
procedures.
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